Compare

NAD+ vs Semaglutide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
XRedditFacebook

NAD+

96 community reports

Positive 2% · Neutral 98% · Negative 0%

Most reported benefits

Energy
197
Appetite
197

Most reported side effects

Headache
66
Nausea
64
Injection site irritation
64

Dose distribution

Median: 2000+ mcg · Most common: 2000+ mcg

0–25
0
25–50
0
50–100
0
100–200
2
200–400
17
400–600
8
600–1000
1
1000–2000
2
2000+
167

How repeat users are trending

Among repeat reporters, 95% said they felt similar to their last entry, 5% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 51 days · Based on 42 repeat reporters

Semaglutide

26 community reports

Positive 4% · Neutral 96% · Negative 0%

Most reported benefits

Appetite
122

Most reported side effects

Nausea
117

Dose distribution

Median: 1000–2000 mcg · Most common: 2000+ mcg

0–25
32
25–50
0
50–100
0
100–200
0
200–400
5
400–600
4
600–1000
9
1000–2000
33
2000+
39

How repeat users are trending

Among repeat reporters, 78% said they felt similar to their last entry, 22% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 94 days · Based on 23 repeat reporters